Navigation Links
Selexis Launches Biosimilar Cell Line Development Program
Date:3/30/2009

As the world leader of cell line manufacturing, Selexis is now offering a portfolio of cell lines expressing biosimilar recombinant protein drugs with added characterization services

GENEVA, March 31 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company offering technologies and services for the rapid development of high-performance stable production cell lines announced today an expanded offering focusing on the biosimilar market segment. Under the new program, Selexis will offer clients the contract development of high producing mammalian cell lines expressing biosimilars, including expanded characterization capabilities. Selexis scientists have already demonstrated, using the Selexis SURE Cell Line Development(SM) Platform, the production of biosimilars proteins at levels as much as 50 fold greater than the currently marketed drugs. The Selexis' SURE Cell Line Development(SM) platform combines Selexis' Intellectual Property rights (e.g. novel genetic elements DNA sequences and transfection procedures) with its cell culture know-how for the rapid development of biosimilars products.

Dr. Igor Fisch, President and CEO of Selexis, commented:

"We feel it is a very important step towards the creation of a global company offering fully integrated services to our client worldwide by including biosimilar expressing cell lines Importantly, in support of this new offer, we are also expanding our support of product characterization capabilities which will further enhance the value of this package".

By combining proprietary technologies with know-how on a fully integrated platform, Selexis can provide top performance cell lines in a industry-known and accepted package.

About Biosimilars:

Biosimilars or Follow-on biologics are terms used to describe officially approved new versions of innovator biopharmaceutical products, following patent expiry.

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements(TM) using the SURE Cell Line Development(SM) process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.


'/>"/>
SOURCE Selexis
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. First Application to Fight High Cholesterol Launches on the iPhone and iPod Touch
2. Merck Serono Launches Strategic Venture Capital Fund
3. Boston Scientific Launches New Coronary Imaging Catheter
4. LUMEDX Launches New Interventional Radiology Software
5. Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition
6. StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies
7. PDHI Launches Short Form of Its ConXus Profile Health Assessment
8. Zymes Omega Solutions Bottles and Launches the Worlds First Omega-3 Enhanced Water
9. Irvine Scientific Launches IS CHO-CD XP(TM)
10. Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers
11. Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Vermillion, Inc. (NASDAQ: VRML), a bio-analytical ... its results for the fourth quarter and full ... marked a pivotal year for us with our ... distribution agreements, major reimbursement progress with Medicare, positive ... In addition we cleared our 2 nd ...
(Date:3/29/2017)... 29, 2017 /PRNewswire/ - Last year,s petition to the White ... only efforts active to generate awareness on the importance of new ... in the healthcare market place. ... Earlier this month Health Advance (OTC ... pharmaceutical and nutritional products, announced its endeavors on this generally ...
(Date:3/29/2017)... ... 29, 2017 , ... (March 29, 2017) — Nerium ... as an active member of the Mexican Direct Selling Association A.C. (AMVD ... in relationship marketing. This professional organization fosters loyal and fair competition among companies ...
(Date:3/29/2017)... March 29, 2017  Halozyme Therapeutics, Inc. (NASDAQ: ... drug-delivery therapies, today announced that an Oncologic Drug ... Administration voted 11 to 0 that the benefit/risk ... was favorable for patients in the proposed indications ... chronic lymphocytic leukemia. The FDA action date is ...
Breaking Biology Technology:
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/2/2017)... LONDON , March 2, 2017 Who ... infringement lawsuits? Download the full report: https://www.reportbuyer.com/product/4313699/ ... ON THE FINGERPRINT SENSOR FIELD? Fingerprint sensors using ... smartphones. The fingerprint sensor vendor Idex forecasts an increase ... in mobile devices and of the fingerprint sensor market ...
(Date:2/28/2017)... --  Acuant , a leading provider of data capture ... new and core technologies building upon the acquisition of ... desktop Acuant FRM TM facial recognition and match ... manual review of identity documents by accredited professionals. ... most accurate capture software to streamline workflows by securely ...
Breaking Biology News(10 mins):